Skip to main content
. 2021 Nov 3;12(4):1928–1942. doi: 10.1016/j.apsb.2021.10.028

Figure 8.

Figure 8

Efficacy of combination treatment of TF-TCB and nivolumab in vitro. (A) Relative TF expression on AsPC-1 and NCI-H292 cell lines, detected by flow cytometry. Orange histogram, tumor cells stained with FITC-labeled anti-TF antibody; black histogram, Blank Control. (B) Relative PD-L1 expression on AsPC-1 and NCI-H292 cell lines, detected by flow cytometry. Green histogram, tumor cells stained with APC-labeled anti-PD-L1 antibody; Black histogram, Blank Control. (C) PD-1 staining of CD3+ T cells after 36 h of incubation. (D) PD-L1 staining of AsPC-1 and NCI-H292 cells after 36 h of incubation. (E) Percentage of tumor cell lysis detected after 36 h of incubation of target cells (AsPC-1 and NCI-H292) with test antibodies and PBMC. Data are mean ± SD, n = 3.